Evaxion Biotech A/S

General Information

We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Drug discovery and clinical development using historically prevailing techniques is a long, costly process with a high attrition rate. We believe our proprietary AI-immunology platforms, trained to translate vast amounts of data into a deep understanding of biological processes in the human body, can be harnessed to rapidly and cost effectively design and develop unique immunotherapies, thereby potentially revolutionizing the process of drug discovery and development.

(Note: Evaxion Biotech priced its IPO on Feb. 4, 2021, with 3.0 million shares, up from 2.8 million shares, at $10, the low end of its $10-to-$12 price range.)

Employees: 35
Founded: 2008
Contact Information
Address Bredgade 34E 1260 Copenhagen K Denmark
Phone Number +45 53 53 18 50
Web Address
View Prospectus: Evaxion Biotech A/S
Financial Information
Market Cap $208.45mil
Revenues $0 mil (last 12 months)
Net Income $-14.3 mil (last 12 months)
IPO Profile
Symbol EVAX
Exchange NASDAQ
Shares (millions): 3.0
Price range $10.00 - $10.00
Est. $ Volume $30.0 mil
Manager / Joint Managers Oppenheimer & Co.
CO-Managers Ladenburg Thalmann
Expected To Trade: 2/5/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change